Posted: November 7th, 2018
Coloplast A/S v. MacGregor Healthcare Limited, UK Intellectual Property Enterprise Court, 24 October 2018, [2018] EWHC 2797 (IPEC) This is a first instance decision from the UK Intellectual Property Enterprise Court “IPEC” on the validity and infringement of European Patent (UK) 1 145 729. The patent claimed a ready-to-use urinary catheter assembly which is stored […]
READ MORE
Posted: November 6th, 2018
G.D. Searle LLC. v. Sandoz B.V., PI Judge District Court The Hague, 1 November 2018, Case no. ECLI:NL:RBDHA:2018:13017 Sandoz, without any prior warning, introduced a generic version of Prezista® at risk on the Dutch market. Sandoz included its product in the October version of the ‘G-Standaard’, which is the Dutch database containing information on all […]
READ MORE
Posted: November 6th, 2018
Icescape Limited v Ice-World International BV & Ors, Court of Appeal, London, UK, 10 October 2018, [2018] EWCA Civ 229 On 10 October 2018 the Court of Appeal handed down judgment in this case which concerned two companies both engaged in the making, operating and leasing of mobile ice rinks. Ice-World was the proprietor of […]
READ MORE
Posted: November 1st, 2018
Court of Milan overturns first instance decision on appeal (“reclamo”) and orders a preliminary injunction based on equivalent infringement of Eli Lilly’s Alimta® patent In a decision of 15th October 2018 in urgent proceedings, the Court of Milan’s appeal panel (comprised of President and Judge rapporteur, Mr Claudio Marangoni and Judges Anna Bellesi and Alima […]
READ MORE
Posted: November 1st, 2018
Unwired Planet International Ltd v Huawei Technologies Co Ltd, Court of Appeal, London, UK [2018] EWCA Civ 2344 On 23 October 2018, the Court of Appeal handed down its judgment in Unwired Planet v Huawei on FRAND licensing of standard-essential patents (‘SEPs’). The Court of Appeal dismissed all three grounds of Huawei’s appeal and upheld […]
READ MORE
Posted: October 26th, 2018
MSD v. Teva, Pharmachemie and centrafarm, Court of Appeal The Hague, 23 October 2018 The Court of Appeal in interlocutory proceedings finds that MSD’s SPC for the combination product of ezetimibe and simvastatin is likely to be found invalid in proceedings on the merits in view of Article 3 c) of Regulation No 469/2009 (“SPC […]
READ MORE
Posted: October 18th, 2018
Samsung Electronics Co Ltd v. Yorcom Computers B.V., Maxperian NL B.V. and Digital Revolution B.V. (joined cases), District Court The Hague, The Netherlands, 17 October 2018, Case no. ECLI:NL:RBDHA:2018:12290 Samsung holds EP 327, EP 559 en EP 701 relating to ink cartridges and sues Maxperian, Digital Revolution and Yorcom for patent infringement. Yorcom et al […]
READ MORE
Posted: October 12th, 2018
Chugai Pharmaceutical v UCB & Celltech [2018] EWHC 2264 (Pat) In his judgment of 24 August 2018 Birss J held that Chugai was not required to pay royalties to UCB in relation to their immunosuppressive drug tocilizumab, marketed as Actemra. The case concerned a worldwide licence granted by the First Defendant, UCB, to the Claimant, […]
READ MORE
Posted: October 9th, 2018
Merck Sharp & Dohme Corp. vs. ratiopharm GmbH et al., District Court of Düsseldorf, 1 October 2018, docket no. 4b O 39/18 – Ezetimibe/Simvastatin The Düsseldorf District Court recently overturned several preliminary injunctions (“PIs”) that it had initially granted ex parte against generic companies, including ratiopharm GmbH. The case concerns the German supplementary protection certificate […]
READ MORE
Posted: October 5th, 2018
Opinion of Advocate General Kokott, 4 October 2018, Case C‑423/17, Staat der Nederlanden v. Warner-Lambert Company LLC A communication whereby the marketing authorisation applicant or holder for a generic medicine, notifies the authority that he is not including in the summary of product characteristics and the package leaflet, those parts of the summary of product […]
READ MORE
EMAIL US
